Researchers believe that the vulnerability of PRMT5 in MTAP‐deficient cancers may extend both upstream of PRMT5 (methionine adenosyltransferase 2A, MAT2A) and downstream of PRMT5 (RIOK1 and other PRMT5 co‐complex members). The gene discussed is MAT2A; the disease is cancer.